45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2

Chiun‐Sheng Huang(National Taiwan University Hospital), George W. Sledge(Caris Life Sciences (United States)), Hao‐Chien Wang(National Taiwan University), Antonio Llombart‐Cussac(MedSIR (Spain)), Joohyuk Sohn(Yonsei University), Nadine Haddad(Eli Lilly (United States)), Norikazu Masuda(Kyoto University), Sachi Sakaguchi(Juntendo University Hospital), Karla Hurt(Eli Lilly (United States)), Masakazu Toi(Mukogawa Women's University), S-A. Im(Seoul National University Hospital), Yi Lu(Shandong Provincial Hospital), Patrick Neven(KU Leuven), Y-H Im(Samsung Medical Center), Hiroji Iwata(Aichi Cancer Center)
Annals of Oncology
November 1, 2020
10.1016/j.annonc.2020.10.065
Cited by 0

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k